PeptidePros
All Peptides

GHRP-6

Also known as: GH-releasing peptide 6

Evidence Tier Bhigh riskintermediatenot approved

GH secretagogue with phase I PK data in humans. FDA has flagged compounding safety concerns.

FDA Safety Flag

The FDA has identified this substance as one that may present significant safety risks when used in compounding, including concerns about immunogenicity, impurity characterization, and/or insufficient safety information.

WADA S2

This substance falls under WADA S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics). If you are subject to anti-doping rules, this category of substances is prohibited at all times.

GH Axis

This substance modulates the growth hormone axis. GH-axis stimulation carries risks including glucose intolerance, fluid retention, and theoretical concerns about sustained IGF-1 elevation.

Overview

GHRP-6 is a GH-releasing peptide. Phase I PK work included escalating single IV bolus doses (100-400 µg/kg) in healthy volunteers. FDA flagged GHRP-6 for compounding safety concerns including immunogenicity/impurities and potential effects on cortisol and blood glucose via decreased insulin sensitivity. PK shows short distribution and hours-scale elimination.

Research Details

Mechanism of Action

GH secretagogue stimulating GH release with smaller ACTH/PRL effects relative to other class members.

Study Dose Range

Human phase I: IV bolus 100-400 µg/kg; physiological studies: 1 µg/kg IV.

Administration Routes

intravenous, subcutaneous

Onset / Timeline

Acute GH response after IV dosing; PK shows hours-scale elimination.

Expected Effects

GH-axis stimulation; appetite stimulation commonly reported.

Adverse Effects

Immunogenicity/impurity concerns (FDA); cortisol effects; decreased insulin sensitivity; glucose metabolism risk.

Contraindications

No formal label.

Interaction Notes

Flag glucose metabolism risk and endocrine-axis spillover as monitoring concerns.

Related Goals
Muscle Growth & StrengthFat Loss & MetabolismGH Axis Optimization
Known Interactions

caution with CJC-1295

Additive GH-axis stimulation plausible; FDA flags both compounds in compounding safety-risk context.

caution with Sermorelin

GHRH analog + GHS-R agonist: additive GH release plausible.

caution with Ipamorelin

Multiple GHS/GHS-R stimulation; FDA flags both for compounding risks/limited safety info.

caution with GHRP-2

Multiple GHS/GHS-R stimulation; higher uncertainty.

caution with MK-677

Redundant GHSR stimulation with added appetite and glucose-management downside.

Available From

No vendors currently listed for this peptide.

Frequently Compared

CJC-1295

Long-acting GHRH analogue studied in human trials for sustained GH/IGF-1 elevation.

Tier B

Sermorelin

GHRH(1-29) analogue that stimulates pulsatile GH secretion, historically used in clinical settings.

Tier B

Tesamorelin

FDA-approved GHRH analogue for HIV-associated lipodystrophy. Prescription only.

Tier A

Ipamorelin

Selective GHSR agonist profiled for more targeted GH release with less ACTH/cortisol spillover than earlier secretagogues.

Tier B-C

Information provided for educational and research reference only. Not medical advice. Not for diagnosing, treating, curing, or preventing disease. Products referenced are labeled Research Use Only (RUO) by vendors; not for human or veterinary use.